TY - JOUR
T1 - Vascular endothelial growth factor in eye disease
AU - Penn, J. S.
AU - Madan, A.
AU - Caldwell, R. B.
AU - Bartoli, M.
AU - Caldwell, R. W.
AU - Hartnett, M. E.
N1 - Funding Information:
The authors are indebted to Susan E. Yanni for her contributions to the editing and processing of this review. Its preparation was funded in part by EY007533, EY08126, EY07135 and support from RPB (JSP); EY04618, EY011766, VA Merit Review Award (RBC); EY015130, EY017011 (MEH).
PY - 2008/7
Y1 - 2008/7
N2 - Collectively, angiogenic ocular conditions represent the leading cause of irreversible vision loss in developed countries. In the US, for example, retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration are the principal causes of blindness in the infant, working age and elderly populations, respectively. Evidence suggests that vascular endothelial growth factor (VEGF), a 40 kDa dimeric glycoprotein, promotes angiogenesis in each of these conditions, making it a highly significant therapeutic target. However, VEGF is pleiotropic, affecting a broad spectrum of endothelial, neuronal and glial behaviors, and confounding the validity of anti-VEGF strategies, particularly under chronic disease conditions. In fact, among other functions VEGF can influence cell proliferation, cell migration, proteolysis, cell survival and vessel permeability in a wide variety of biological contexts. This article will describe the roles played by VEGF in the pathogenesis of retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration. The potential disadvantages of inhibiting VEGF will be discussed, as will the rationales for targeting other VEGF-related modulators of angiogenesis.
AB - Collectively, angiogenic ocular conditions represent the leading cause of irreversible vision loss in developed countries. In the US, for example, retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration are the principal causes of blindness in the infant, working age and elderly populations, respectively. Evidence suggests that vascular endothelial growth factor (VEGF), a 40 kDa dimeric glycoprotein, promotes angiogenesis in each of these conditions, making it a highly significant therapeutic target. However, VEGF is pleiotropic, affecting a broad spectrum of endothelial, neuronal and glial behaviors, and confounding the validity of anti-VEGF strategies, particularly under chronic disease conditions. In fact, among other functions VEGF can influence cell proliferation, cell migration, proteolysis, cell survival and vessel permeability in a wide variety of biological contexts. This article will describe the roles played by VEGF in the pathogenesis of retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration. The potential disadvantages of inhibiting VEGF will be discussed, as will the rationales for targeting other VEGF-related modulators of angiogenesis.
KW - Age-related macular degeneration
KW - Angiogenesis
KW - Diabetic retinopathy
KW - Retina
KW - Retinopathy of prematurity
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=48549088705&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=48549088705&partnerID=8YFLogxK
U2 - 10.1016/j.preteyeres.2008.05.001
DO - 10.1016/j.preteyeres.2008.05.001
M3 - Review article
C2 - 18653375
AN - SCOPUS:48549088705
SN - 1350-9462
VL - 27
SP - 331
EP - 371
JO - Progress in Retinal and Eye Research
JF - Progress in Retinal and Eye Research
IS - 4
ER -